Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vaginal Dysbiosis, Bacterial Vaginosis (BV)
- Main trialPhase 2
- “The goal of this clinical trial is to evaluate FB301 during a mock frozen embryo transfer (FET) cycle in pre-menopausal women aged 18 to 45 years with a prior failed FET and a defined vaginal bacterial imbalance (dysbiosis). The main question it aims to answer is: • Does treatment with FB301 during a mock FET cycle change the proportion of participants who meet the predefined vaginal bacterial threshold compared with placebo? Researchers will compare: * FB301 given after an initial vaginal cleansing with chlorhexidine (an antiseptic solution), * FB301 given after an initial vaginal…”In the company’s words, NCT07453069 on ClinicalTrials.gov
Other drugs for Bacterial Vaginosis (BV)
- BPR-101Chengdu Syncor Pharmaceutical Co., Ltd. · Phase 2
- WST03 Vaginal MetronidazoleSPH Sine Pharmaceutical Laboratories Co., Ltd. · Phase 2
- GenSci142Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up1
- 3 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2026 | Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle | |
| Phase 2Recruiting | 3 Mar 2027 | Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026